This content is machine translated HER2+ early breast cancer DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines The phase III DESTINY-Breast11 trial shows that neoadjuvant trastuzumab deruxtecan (T-DXd) could provide an anthracycline-free treatment option for HER2-positive early breast cancer. The results suggest an effective and better tolerated...…
View Post 14 min This content is machine translated New approvals, current study data and ADC development Antibody-drug conjugates in gynecologic oncology Antibody-drug conjugates (ADCs) have profoundly changed gynecological oncology in a very short space of time. Within just two years, three ADCs – mirvetuximab soravtansine, tisotumab vedotin and trastuzumab deruxtecan –...…
